Sava, the London-based startup pioneering real-time molecular health monitoring, today announced $19 million in Series A funding, following promising early results from its clinical trial.... The post Sava raises $19M Series A amid world-first clinical results for next-gen biosensor first appeared on Balderton Capital.
